Pelvic Inflammatory Disease (PID) Treatment Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Pelvic Inflammatory Disease (PID) Treatment Market?
In recent times, the market size for the treatment of pelvic inflammatory disease (PID) has seen significant growth. The market is expected to expand from $4.49 billion in 2024 to $4.75 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.8%. The notable growth in the past period is a result of increased usage of telemedicine, a surge in sexually transmitted infections, heightened understanding of pelvic inflammatory disease, and elevated spending on healthcare.

The market for treatment of pelvic inflammatory disease (PID) is anticipated to witness a robust growth in the coming years. It is predicted to reach $5.88 billion by 2029, expanding at a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this growth during the forecast period include an increase in sexually transmitted infections, heightened awareness about female reproductive health, more knowledge about pelvic inflammatory disease, a growing dependency on telehealth services, and an increased rate of sexually transmitted infections (STIs). Some key trends for the forecast period comprise innovative treatment products for pelvic inflammatory disease, advancements in diagnostic technology, novel concepts like personalized treatment, sophisticated imaging techniques and technological progress.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21251

What Are the Different Pelvic Inflammatory Disease (PID) Treatment Market Segments?
The pelvic inflammatory disease (PID) treatment market covered in this report is segmented -

1) By Treatment Type: Antibiotic Therapy, Surgery, Pain Management, Hormonal Therapy
2) By Route Of Administration: Oral, Intravenous, Intramuscular
3) By End User: Hospitals, Clinics, Homecare

Subsegments:
1) By Antibiotic Therapy: Broad-spectrum Antibiotics, Combination Antibiotic Therapy, Oral Antibiotics, Intravenous Antibiotics
2) By Surgery: Laparoscopy, erec*tomy, Tubal Surgery
3) By Pain Management: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen, Localized Pain Management
4) By Hormonal Therapy: Birth Control Pills, Hormonal Intrauterine Device (IUD), Progesterone Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21251&type=smp

What Are the Primary Drivers Shaping the Pelvic Inflammatory Disease (PID) Treatment Market?
The spike in cases of sexually transmitted infections is projected to spur the expansion of the pelvic inflammatory disease (PID) treatment market. Sexually transmitted infections (STIs), caused by a variety of bacteria, viruses or parasites, are predominantly spread through sexual contact, including vaginal, anal or oral engagement. The upsurge in STIs stems from risky sexual activities, unprotected intercourse, inadequate knowledge, procrastinated testing and treatment. The treatment of PID plays a pivotal role in managing STIs as it involves usage of antibiotics to eradicate infection-causing bacteria, avert complications like chronic pelvic pain and infertility, and minimize the possibility of recurrent infections. For example, a report by the UK Health Security Agency (UKHSA), a government agency from the UK, states that England recorded 6,008 new cases of human immunodeficiency virus (HIV) in 2023, signifying a 51% rise in comparison to the 3,975 diagnoses made in 2022. Thus, the growing incidence of sexually transmitted infections is fuelling the demand in the PID treatment market.

Which Companies Are Leading in the Pelvic Inflammatory Disease (PID) Treatment Market?
Major companies operating in the pelvic inflammatory disease (PID) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., Amagen India Life Sciences.

What Are the Latest Developing Trends in the Pelvic Inflammatory Disease (PID) Treatment Market?
Leading firms in the pelvic inflammatory disease (PID) treatment market, are focusing their efforts on the development of innovative formulations like probiotic supplements. These new supplements are designed to enhance the effectiveness of treatments, help reinstate the balance of vaginal microbiota, and decrease the recurrence of infections amongst PID patients. Probiotic supplements are products comprised of beneficial bacteria or yeasts that boost or restore the healthy balance of both gut and vaginal microbiota. For example, Lee Health Domain, a pharmaceutical company from India, rolled out V-Ferin in November 2024. This is a probiotic supplement specifically tailored for vaginal health. It's composed of Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract all of which work together to reestablish the natural microbiome and combat common vaginal infections such as bacterial vaginosis and yeast infections. As around 25-30% of women experience these conditions that can develop into PID if not treated, V-Ferin presents an innovative resolution for enhancing health and staving off complications.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/pelvic-inflammatory-disease-pid-treatment-global-market-report

What Are the Top Revenue-Generating Geographies in the Pelvic Inflammatory Disease (PID) Treatment Market?
North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pelvic inflammatory disease (PID) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Pelvic Inflammatory Disease (PID) Treatment Market?
2. What is the CAGR expected in the Pelvic Inflammatory Disease (PID) Treatment Market?
3. What Are the Key Innovations Transforming the Pelvic Inflammatory Disease (PID) Treatment Industry?
4. Which Region Is Leading the Pelvic Inflammatory Disease (PID) Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.